- RINVOQ demonstrated significant improvements to signs and symptoms of active ankylosing spondylitis[1]
- In a pivotal Phase 2/3 study, twice as many patients receiving RINVOQ achieved the primary endpoint of ASAS 40 response at week 14 compared to placebo (p